Vancomycin
Liver Metastasis
National Cancer Institute (NCI)Small moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 81/ 100
Competitive context
16 Active assets in the Liver Metastasis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Eloxatin Tianjin Medical University Cancer Institute and Hospital | Phase 3 | BB |
Calcium folinate pentahydrate National Taiwan University Hospital | Phase 3 | BB |
Talaporfin Light Sciences LLC | Phase 2 | BB |
FLUOROURACILUM National Taiwan University Hospital | Phase 3 | BB |
Irinotecan Tianjin Medical University Cancer Institute and Hospital | Phase 3 | B |
View all 30 →
Same molecule, other indications
Vancomycin is also rated in:
methicillin-resistant staphylococcus aureus infectious diseaseDormant
BB
Indicative ·
68 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →